Compare Procter & Gamble Health with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs CIPLA - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH CIPLA PROCTER & GAMBLE HEALTH/
CIPLA
 
P/E (TTM) x 55.4 24.3 228.0% View Chart
P/BV x 5.0 2.5 202.0% View Chart
Dividend Yield % 9.5 0.6 1,460.6%  

Financials

 PROCTER & GAMBLE HEALTH   CIPLA
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
CIPLA
Mar-19
PROCTER & GAMBLE HEALTH/
CIPLA
5-Yr Chart
Click to enlarge
High Rs3,549678 523.5%   
Low Rs1,301484 269.0%   
Sales per share (Unadj.) Rs511.4198.2 258.0%  
Earnings per share (Unadj.) Rs61.318.5 330.9%  
Cash flow per share (Unadj.) Rs74.035.0 211.6%  
Dividends per share (Unadj.) Rs440.003.00 14,666.7%  
Dividend yield (eoy) %18.10.5 3,513.1%  
Book value per share (Unadj.) Rs927.8186.3 497.9%  
Shares outstanding (eoy) m16.60805.70 2.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.72.9 161.8%   
Avg P/E ratio x39.631.4 126.2%  
P/CF ratio (eoy) x32.816.6 197.3%  
Price / Book Value ratio x2.63.1 83.8%  
Dividend payout %717.916.2 4,432.7%   
Avg Mkt Cap Rs m40,257468,031 8.6%   
No. of employees `0001.122.6 5.0%   
Total wages/salary Rs m1,31328,565 4.6%   
Avg. sales/employee Rs Th7,486.77,053.1 106.1%   
Avg. wages/employee Rs Th1,157.61,261.5 91.8%   
Avg. net profit/employee Rs Th897.2659.1 136.1%   
INCOME DATA
Net Sales Rs m8,490159,710 5.3%  
Other income Rs m2444,766 5.1%   
Total revenues Rs m8,734164,475 5.3%   
Gross profit Rs m1,48230,973 4.8%  
Depreciation Rs m21113,263 1.6%   
Interest Rs m01,684 0.0%   
Profit before tax Rs m1,51420,791 7.3%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m660-   
Tax Rs m5635,695 9.9%   
Profit after tax Rs m1,01714,924 6.8%  
Gross profit margin %17.519.4 90.0%  
Effective tax rate %37.127.4 135.6%   
Net profit margin %12.09.3 128.2%  
BALANCE SHEET DATA
Current assets Rs m15,343124,266 12.3%   
Current liabilities Rs m1,96037,715 5.2%   
Net working cap to sales %157.654.2 290.9%  
Current ratio x7.83.3 237.6%  
Inventory Days Days4991 53.8%  
Debtors Days Days2895 30.0%  
Net fixed assets Rs m1,209105,190 1.1%   
Share capital Rs m1661,611 10.3%   
"Free" reserves Rs m15,235148,511 10.3%   
Net worth Rs m15,401150,123 10.3%   
Long term debt Rs m038,301 0.0%   
Total assets Rs m17,595239,633 7.3%  
Interest coverage xNM13.3-  
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.50.7 72.4%   
Return on assets %5.86.9 83.4%  
Return on equity %6.69.9 66.4%  
Return on capital %10.311.8 86.7%  
Exports to sales %034.7 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,419 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,63657,410 2.9%   
Fx outflow Rs m4,36819,041 22.9%   
Net fx Rs m-2,73238,368 -7.1%   
CASH FLOW
From Operations Rs m-1,30416,911 -7.7%  
From Investments Rs m12,697-16,687 -76.1%  
From Financial Activity Rs m-301-3,487 8.6%  
Net Cashflow Rs m11,093-3,451 -321.4%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 51.8 20.8 249.0%  
Indian inst/Mut Fund % 18.2 12.2 149.2%  
FIIs % 1.0 23.7 4.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 29.1 26.2 111.1%  
Shareholders   28,591 161,166 17.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   JUBILANT LIFE SCIENCES  PANACEA BIOTECH  CADILA HEALTHCARE  ABBOTT INDIA  PLETHICO PHARMA  

Compare PROCTER & GAMBLE HEALTH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Sep 20, 2019 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 5-YR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS